Atrial fibrillation and heart failure coexist in many patients; what is the best management plan for them? In this interview, Uma Narasimhan Srivatsa, MBBS, FACC; Anthony Tang, MD; and Anthony J. Mazzella, MD, discuss RAFT-AF (A Randomized Ablation-Based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and High Burden Atrial Fibrillation). For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

Severe aortic stenosis may go unrecognized, and therefore untreated, in the setting of a low gradient, even if all data point to the existence of a low-flow, low-gradient state and a severe degree of stenosis. In this interview, Mirvat Alasnag, MB, BCH, FACC; Patricia Pellikka, MD, FACC; and Matt Cavender, MD, MPH, FACC, discuss when low-flow, low-gradient aortic stenosis is considered severe. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean Pinney, MD, FACC; Brad Williams, PharmD; and Nosheen Reza, MD, discuss strategies to maximize doses and introduce new medications in a busy practice. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

The ATLANTIS trial will change the way antithrombotic treatments are chosen after successful transcatheter aortic valve implantation. In this interview, Roxana Mehran, MD, FACC; Jean-Philippe Collet, MD; and Zaid I. Almarzooq, MBBCh, discuss anti-xa oral anticoagulation after valve implantation for aortic stenosis. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

Telemedicine use has surged over the past year, and this may pose a risk to the quality of care if standards aren't applied to its practice and use. In this interview, Alison Bailey, MD, FACC; Jeff Wessler, MD, MPhil, FACC; and Estefania Oliveros, MD, MSc, discuss the challenge of increasing utilization of telemedicine without robust data. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

In this interview, Spencer King III, MD, MACC; Michael Reardon, MD; and Michelle Kelsey, MD, discuss the natural history of asymptomatic severe aortic stenosis and the association of early intervention with outcomes. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be considered in patients with NICM and left bundle branch block? What were the data to support the use of ICDs for primary prevention in NICM? In this episode, Rachel Lampert, MD, moderates a debate between Michael R. Gold, MD, PhD, and Eric N. Prystowsky, MD, FACC, about whether primary prevention ICDs are still a valuable therapy in patients with NICM. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration of high doses of a carboxylic formulation containing both eicosapentaenoic acid and docosahexaenoic acid, but it did show an increase in risk of atrial fibrillation. In this interview, Steven E. Nissen MD, MACC; Stephen J. Nicholls MBBS, PhD, FACC; and Michael Mikolaj MD, MPH, FACC, discuss STRENGTH and whether omega-3 fatty acids produce net benefit or harm. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

In this interview, Peter McCullough, MD, MPH, FACC; Steve Ommen, MD, FACC; and Poonam Velagapudi, MD, MS, discuss top takeaways from the 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.

Many older patients find it difficult to take many medications, especially if the medication regimens of "polypharmacy" are complicated, but would we ever consider deprescribing life-extending medications? In this interview, Laxmi Mehta MD, FACC; James N. Kirkpatrick, MD, FACC, FASE, Chair of ACC Geriatrics Section; and Payal Kohli MD, FACC, discuss polypharmacy in the geriatric patient. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.